Semax is one of the most extensively studied synthetic peptides in Russian neuroscience literature, yet it remains relatively underexplored in North American research circles. For Canadian investigators interested in neuropeptide pharmacology, cognitive function studies, or neuroprotection models, Semax represents a compelling tool compound.
What Is Semax?
Semax is a synthetic heptapeptide originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It was designed as a stable analog of the ACTH (adrenocorticotropic hormone) 4-10 fragment, a small segment of the larger ACTH molecule known to carry neurotropic activity independent of ACTH's hormonal effects on the adrenal cortex.
The ACTH 4-10 fragment itself had been investigated since the 1960s for its influence on learning and memory in animal models, but the native fragment proved too unstable for practical research use, with a half-life of only minutes in biological fluids. Russian researchers addressed this limitation by appending a C-terminal Pro-Gly-Pro tripeptide extension.
The Heptapeptide Structure
Semax consists of seven amino acids in the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the 4-7 portion of native ACTH, while the Pro-Gly-Pro tail is a synthetic addition that confers resistance to peptidase degradation.
How Semax Differs From Native ACTH
Native ACTH (1-39) binds the melanocortin-2 receptor in the adrenal cortex, triggering cortisol release and a cascade of endocrine effects. The 4-10 fragment, and by extension Semax, lacks the residues required for efficient adrenal receptor activation. The practical consequence is that Semax does not appear to stimulate cortisol release or produce the hormonal confounds that complicate studies involving the parent hormone.
Mechanism of Action in Preclinical Research
BDNF and Neurotrophin Upregulation
One of the most reproducible findings in Semax research is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in rodent hippocampal tissue. A widely cited study by Dolotov and colleagues published in the Journal of Neurochemistry demonstrated rapid induction of BDNF and TrkB expression in rat hippocampus following intranasal Semax administration.
Dopaminergic and Serotonergic Modulation
Preclinical research indicates that Semax influences monoaminergic signaling, with reported effects on dopamine and serotonin turnover in rodent brain regions associated with attention and affective processing.
Neuroprotection Pathways
In ischemia and oxidative stress models, research has examined Semax's influence on inflammatory cytokines, antioxidant enzyme expression, and neuronal survival following insult. These neuroprotection studies have been a major focus of Russian research programs.
Why Nasal Delivery in Research Protocols
Semax is almost always administered intranasally in published research protocols. Peptides are generally poor candidates for oral administration due to proteolytic degradation in the gastrointestinal tract, and systemic injection requires the peptide to cross the blood-brain barrier (BBB) to reach CNS targets.
Intranasal administration offers a direct rostral route to the central nervous system via the olfactory and trigeminal pathways, bypassing first-pass metabolism and reducing the BBB transit problem. Researchers replicating published Semax protocols typically adhere to intranasal administration to maintain consistency with the established literature. Our Semax research material is prepared with this delivery format in mind.
Research Categories Where Semax Appears
Cognitive Function Studies
Semax has been investigated in rodent models of learning and memory, including Morris water maze and passive avoidance paradigms. The underlying hypothesis is that neurotrophin upregulation supports synaptic plasticity relevant to cognitive endpoints.
Neuroprotection Research
Middle cerebral artery occlusion (MCAO) models in rats have been a mainstay of Semax research, examining infarct size, neurological deficit scores, and molecular markers of inflammation following ischemic insult.
Neuroplasticity Studies
Studies have examined dendritic morphology, long-term potentiation, and gene expression profiles in hippocampal tissue following Semax exposure.
Regulatory Status and the Canadian Research Context
Semax has been used in clinical settings in Russia for decades but is not approved by Health Canada or the US FDA for human use. For Canadian laboratories, this means Semax is available strictly as a research chemical for in vitro and preclinical investigation.
This regulatory distinction is important. Canadian researchers working with Semax should ensure their institutional review processes, chemical inventory documentation, and biosafety protocols clearly designate the compound as a research-use-only material.
Sourcing Research-Grade Semax in Canada
Research-grade Semax should be supplied with a third-party certificate of analysis documenting HPLC purity, mass spectrometry confirmation of identity, and batch-level traceability. Without this documentation, data generated from the material cannot be meaningfully compared to published literature.
Based Peptides is a Canadian supplier focused on the research chemical market. Researchers can Buy Semax in Canada through our catalog, and our product listings include batch-specific certificate of analysis documentation. For investigators comparing Semax alongside other neuropeptide research compounds, related listings include BPC-157, TB-500, and CJC-1295 DAC.
Conclusion
Semax occupies a distinctive niche in neuropeptide research: a well-characterized heptapeptide with decades of published preclinical data, a clear mechanistic profile centered on neurotrophin modulation, and a delivery format that supports reproducible CNS exposure. For Canadian researchers investigating neuroprotection, cognition, or neuroplasticity in preclinical models, Semax is a compound worth considering.
Research Use Only Disclaimer: Semax is supplied as a research chemical intended strictly for in vitro and preclinical laboratory investigation by qualified researchers. It is not approved by Health Canada or the US FDA for human use, diagnosis, treatment, cure, or prevention of any disease.